CML-121: Efficacy and Safety of Asciminib in Heavily Pretreated Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Sensitivity to Tyrosine Kinase Inhibitors (TKIs)
Year: 2020
Type: conference-abstract
Institutions: South Australian Health and Medical Research Institute, The University of Adelaide, Memorial Sloan Kettering Cancer Center, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Hôpital Saint-Louis, Kobe University Hospital, Sapienza University of Rome, Dana-Farber Cancer Institute, Jena University Hospital, Singapore General Hospital, Charité – Universitätsmedizin Berlin, Goethe University Frankfurt, Novartis (Switzerland), Novartis (Ireland), University of Michigan
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3111468087